The EPS projection of Regulus Therapeutics Inc. (NASDAQ:RGLS) for quarter ended 2016-09-30 is $-0.39. A week before, the EPS forecast was $-0.39 against target of $-0.39, a month earlier. This estimate stood at $-0.39 60 days earlier versus forecast of $-0.39 90 days earlier, confirming a deviation of 0%.
Regulus Therapeutics Inc. (NASDAQ:RGLS) reported that 18 days ago, the positive EPS revisions were 0 and negative revisions at 1.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 0, 0, 0 and 0, respectively.
The downgrade of EPS estimates for Regulus Therapeutics Inc. (NASDAQ:RGLS) in the preceding 120, 60, 30 and 90 days were 1, 2, 0 and 2, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Regulus Therapeutics Inc. (NASDAQ:RGLS) was $-0.39. This projection was computed after accounting 4 calls. As reported on 2016-05-02 the EPS was $-0.4. The change was $-0.07, demonstrating a percentage deviation of -21.21%. The projections confirmed a standard deviation of 0.01.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Regulus Therapeutics Inc. (NASDAQ:RGLS) stands at $0.495 and the median estimate at $0.495. Almost 2 analysts announced their estimates.
The highest estimate is $0.5 while the lowest target is $0.49 showing standard deviation of 0.007%.
As many as 2 analysts released sales estimates reised in upside while 2 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 2 revised sales number projection on upside while 2 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 2 hiked sales estimations and 2 reduced sales forecast. Regulus Therapeutics Inc. (NASDAQ:RGLS) stated that the change in forecast was -77.99%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...